A Phase I/II, Open-Label Study of Neratinib (HKI-272) in Combination with Capecitabine in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or Locally Advanced Breast Cancer.

Trial Profile

A Phase I/II, Open-Label Study of Neratinib (HKI-272) in Combination with Capecitabine in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or Locally Advanced Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 May 2015

At a glance

  • Drugs Neratinib (Primary) ; Capecitabine
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Puma Biotechnology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 May 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017, as reported by ClinicalTrials.gov.
    • 17 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top